PHARVARIS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.78 USD | +4.46% |
|
+23.70% | -15.51% |
| Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| Apr. 12 | Pharvaris Files Mixed Shelf | MT |
Chart calendar Pharvaris N.V.
678c61f0def5d.rB89sDaFe33yU0rcvn94KSCAoM3VrH6ks6Dc6BUhPRY.zVhfgXX0MjSqMhOE8TMXQHXSzaqb5Sf24OKDm3ZmdW7OVnriTMoLLJkmJQ~31d13a4a186fac36aa31e70fa0acd216
Upcoming events on Pharvaris N.V.
Past events on Pharvaris N.V.
| 2024-04-13 12:20 pm | Consortium of Independent Immunology Clinics Spring Conference |
| 2024-04-13 12:00 pm | Consortium of Independent Immunology Clinics Spring Conference |
| 2024-04-11 | CIIC Spring Conference |
| 2024-04-10 04:10 pm | Q4 2023 Earnings Release |
| 2024-03-16 11:15 am | HAEi Regional Conference |
| 2024-03-16 09:30 am | HAEi Regional Conference |
| 2024-03-16 05:00 am | ITACA National Congress |
| 2024-03-15 07:20 pm | HAEi Regional Conference - Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucri |
| 2024-03-15 07:20 pm | HAEi Regional Conference - RAPIDe-1 Phase 2 Trial |
| 2024-03-15 07:20 pm | HAEi Regional Conference - RAPIDe-3 Phase 3 Trial Design |
| 2024-03-15 11:30 am | ITACA National Congress - Need for Caregiver Support for People Living |
| 2024-03-15 11:30 am | ITACA National Congress - Prophylactic Treatment with Oral Deucrictibant |
| 2024-03-15 11:30 am | ITACA National Congress - Efficacy and Safety of Bradykinin B2 Receptor Antagonism |
| 2024-03-15 11:30 am | ITACA National Congress - Efficacy and Safety of the Oral Bradykinin B2 Receptor |
| 2024-03-12 10:00 am | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 2024-03-06 06:00 am | Extraordinary Shareholders Meeting |
| 2024-02-23 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting |
| 2024-02-14 08:30 am | Oppenheimer Healthcare Life Sciences Conference |
| 2024-02-08 10:00 am | Bio Capital Europe Conference |
| 2024-01-11 12:00 pm | JPMorgan Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million EUR | Released Forecast Spread | 0,00 | -23,4 -17,0 -37.86% | -45,9 -63,8 28.06% | -75,2 -83,1 9.45% | -86,0 -90,3 4.76% | -101 |
|
EBIT Million EUR | Released Forecast Spread | 0,00 | -25,0 -19,0 -31.29% | -54,1 -60,1 9.98% | -86,7 -84,2 -2.96% | -96,9 -92,8 -4.42% | -117 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 0,00 | -26,1 -20,6 -26.55% | 0,00 0,00 - | -75,7 -60,6 -24.82% | -99,8 -93,4 -6.84% | -122 |
|
Net income Million EUR | Released Forecast Spread | -8,03 | -26,0 -20,6 -26.01% | -42,7 -54,5 21.6% | -76,3 -61,9 -23.37% | -101 -91,9 -9.78% | -115 |
|
EPS EUR | Released Forecast Spread | -1,66 | -5,36 -4,17 -28.54% | -1,40 -2,24 37.41% | -2,27 -1,83 -24.16% | -2,63 -2,30 -14.49% | -2,30 |
| Announcement Date | 12/11/20 | 29/04/21 | 29/03/22 | 05/04/23 | 10/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million EUR | Released Forecast Spread | -18,2 -19,6 7.28% | -24,6 -27,7 11.2% | |||||||||||
|
EBIT Million EUR | Released Forecast Spread | -16,2 -20,8 21.98% | -19,4 -17,9 -8.49% | -21,4 -20,8 -2.56% | -22,4 -22,2 -1.03% | -23,6 -23,8 1.07% | -21,1 -22,9 8.03% | -22,5 -21,4 -4.98% | -26,2 -23,2 -12.91% | -27,2 -26,2 -3.6% | -28,7 | -29,9 | -30,4 | -32,8 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -9,88 -22,4 55.91% | -10,9 -22,4 51.38% | -38,9 -23,9 -63.06% | -21,8 -20,9 -4.2% | -23,5 -22,1 -6.32% | -32,0 -25,6 -24.96% | -27,4 | -28,9 | -29,6 | -32,1 | |||
|
Net income Million EUR | Released Forecast Spread | -12,3 -24,2 48.96% | -16,0 -15,2 -5.28% | -12,6 -19,6 35.56% | -8,50 -21,3 60.09% | -39,2 -20,4 -91.8% | -22,6 -23,8 4.91% | -21,9 -20,8 -5.27% | -23,6 -22,0 -7.21% | -32,7 -25,6 -27.88% | -27,4 | -28,4 | -28,9 | -30,7 |
|
EPS EUR | Released Forecast Spread | -0,09 -0,64 85.86% | -0,48 -0,46 -5.49% | -0,38 -0,59 35.12% | -0,25 -0,63 60.3% | -1,16 -0,58 -99.23% | -0,67 -0,69 2.33% | -0,63 -0,60 -4.83% | -0,58 -0,61 5.29% | -0,76 -0,57 -34.32% | -0,55 | -0,57 | -0,58 | -0,62 |
| Announcement Date | 29/03/22 | 11/05/22 | 12/09/22 | 08/12/22 | 05/04/23 | 08/05/23 | 07/08/23 | 02/11/23 | 10/04/24 | - | - | - | - |
More events
Past sector events for Pharvaris N.V.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PHVS Stock
- Calendar Pharvaris N.V.
